# Salvatore Siena

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/salvatore-siena/

## Facts

| Field | Value |
| --- | --- |
| Citations | 81,679 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 115 |
| i10-index | 415 |
| Last Known Institution | University of Milan |
| OpenAlex ID | https://openalex.org/A5031031537 |
| ORCID iD | https://orcid.org/0000-0002-2681-2846 |
| Works | 1,150 |

## Researcher papers

Showing 12 of 13.

- [Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies](https://scholariq.org/papers/detection-of-circulating-tumor-dna-in-early-and-late-stage-human-malignancies/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/)
- [Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial](https://scholariq.org/papers/efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-expressing/)
- [Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-multitargeted-pan-trk-ros1-and-alk/)
- [Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab](https://scholariq.org/papers/association-of-kras-p-g13d-mutation-with-outcome-in-patients-with-chemotherapy/)
- [Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer](https://scholariq.org/papers/final-results-from-prime-randomized-phase-iii-study-of-panitumumab-with-folfox4/)
- [Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-integrated/)
- [High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma](https://scholariq.org/papers/high-dose-chemotherapy-and-autologous-bone-marrow-transplantation-compared-with/)
- [Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study](https://scholariq.org/papers/overall-survival-improvement-in-patients-with-lung-cancer-and-bone-metastases/)
- [First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial](https://scholariq.org/papers/first-line-erlotinib-followed-by-second-line-cisplatin-gemcitabine-chemotherapy/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [University of Milan](https://scholariq.org/institutions/university-of-milan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.